DUBLIN, Ireland, March 02, 2023 (GLOBE NEWSWIRE) — GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the full year ended December 31, 2022 and gave updates on its business. Business Updates We are pleased to report that we have recently initiated our…


Previous articleAlgernon NeuroScience Appoints Global TBI Expert and Former NFL Neurological Player Care Safety Director Dr. David Brody to Advisory Board
Next articlePT395 – Thank You Life: Accessibility, Fair Compensation, and Trusting Intuition